Home > Research > Publications & Outputs > Mobile Health Biometrics to Enhance Exercise an...

Research

Associated organisational unit

Links

Text available via DOI:

Keywords

View graph of relations

Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada. / Hesketh, Katie; Low, Jonathan; Andrews, Robert et al.
In: BMJ Open, Vol. 15, No. 3, e092260, 26.03.2025.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Hesketh, K, Low, J, Andrews, R, Blitz, S, Buckley, B, Falkenhain, K, Job, J, Jones, CA, Jones, H, Jung, ME, Little, J, Mateus, C, Percival, SL, Pulsford, R, Russon, CL, Singer, J, Sprung, VS, McManus, AM & Cocks, M 2025, 'Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada', BMJ Open, vol. 15, no. 3, e092260. https://doi.org/10.1136/bmjopen-2024-092260

APA

Hesketh, K., Low, J., Andrews, R., Blitz, S., Buckley, B., Falkenhain, K., Job, J., Jones, C. A., Jones, H., Jung, M. E., Little, J., Mateus, C., Percival, S. L., Pulsford, R., Russon, C. L., Singer, J., Sprung, V. S., McManus, A. M., & Cocks, M. (2025). Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada. BMJ Open, 15(3), Article e092260. https://doi.org/10.1136/bmjopen-2024-092260

Vancouver

Hesketh K, Low J, Andrews R, Blitz S, Buckley B, Falkenhain K et al. Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada. BMJ Open. 2025 Mar 26;15(3):e092260. doi: 10.1136/bmjopen-2024-092260

Author

Hesketh, Katie ; Low, Jonathan ; Andrews, Robert et al. / Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D) : a decentralised feasibility randomised controlled trial delivered across the UK and Canada. In: BMJ Open. 2025 ; Vol. 15, No. 3.

Bibtex

@article{22b42a1172a04af4be81bc01573f3c11,
title = "Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D): a decentralised feasibility randomised controlled trial delivered across the UK and Canada",
abstract = "OBJECTIVES: Assess the feasibility of a mobile health (mHealth)-supported home-delivered physical activity (PA) intervention (MOTIVATE-T2D) in people with recently diagnosed type 2 diabetes (T2D).DESIGN: Feasibility multicentre, parallel group, randomised controlled trial (RCT).SETTING: Participants were recruited from England and Canada using a decentralised design.PARTICIPANTS: Adults (40-75 years) recently diagnosed with T2D (5-24 months).INTERVENTIONS: Participants were randomised 1:1 to intervention (MOTIVATE-T2D) or active control groups. Participants codesigned 6month- home-delivered, personalised, progressive PA programmes supported by virtual behavioural counselling. MOTIVATE-T2D used biofeedback from wearable technologies to support the programme. The active control group received the same intervention without wearables.OUTCOMES: The primary outcomes were recruitment rate, retention and adherence to purposeful exercise. Clinical data on effectiveness were collected as exploratory outcomes at baseline, 6 and 12 months, with HbA1c and systolic blood pressure (BP) proposed as primary outcomes for a future full RCT.RESULTS: n=135 eligible participants expressed an interest in the trial, resulting in 125 participants randomised (age 55±9 years, 48% female, 81% white), a recruitment rate of 93%. Retention at 12 months was 82%. MOTIVATE-T2D participants were more likely to start (OR 10.4, CI 3.4 to 32.1) and maintain purposeful exercise at 6 (OR 7.1, CI 3.2 to 15.7) and 12 months (OR 2.9, CI 1.2 to 7.4). Exploratory clinical outcomes showed a potential effect in favour of MOTIVATE-T2D, including proposed primary outcomes HbA1c and systolic BP (between-group mean differences: HbA1c: 6 months: -5% change from baseline, CI -10 to 2: 12 months: -2% change from baseline, CI -8 to -4; systolic BP: 6 months: -1 mm Hg, CI -5 to 3: 12 months: -4 mm Hg, CI -8 to 1).CONCLUSIONS: Our findings support the feasibility of delivering the MOTIVATE-T2D mHealth-supported PA intervention for people with recently diagnosed T2D and progression to a full RCT to examine its clinical and cost-effectiveness.TRIAL REGISTRATION NUMBER: ISRCTN: 14335124; ClinicalTrials.gov: NCT0465353.",
keywords = "Humans, Diabetes Mellitus, Type 2/therapy, Middle Aged, Female, Male, Feasibility Studies, Exercise, Aged, Telemedicine, Canada, Adult, Patient Compliance, Motivation, United Kingdom",
author = "Katie Hesketh and Jonathan Low and Robert Andrews and Sandra Blitz and Benjamin Buckley and Kaja Falkenhain and Jennifer Job and Jones, {Charlotte A} and Helen Jones and Jung, {Mary E} and Jonathan Little and Ceu Mateus and Percival, {Sarah L} and Richard Pulsford and Russon, {Catherine L} and Joel Singer and Sprung, {Victoria S} and McManus, {Alison M} and Matthew Cocks",
note = "{\textcopyright} Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.",
year = "2025",
month = mar,
day = "26",
doi = "10.1136/bmjopen-2024-092260",
language = "English",
volume = "15",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D)

T2 - a decentralised feasibility randomised controlled trial delivered across the UK and Canada

AU - Hesketh, Katie

AU - Low, Jonathan

AU - Andrews, Robert

AU - Blitz, Sandra

AU - Buckley, Benjamin

AU - Falkenhain, Kaja

AU - Job, Jennifer

AU - Jones, Charlotte A

AU - Jones, Helen

AU - Jung, Mary E

AU - Little, Jonathan

AU - Mateus, Ceu

AU - Percival, Sarah L

AU - Pulsford, Richard

AU - Russon, Catherine L

AU - Singer, Joel

AU - Sprung, Victoria S

AU - McManus, Alison M

AU - Cocks, Matthew

N1 - © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.

PY - 2025/3/26

Y1 - 2025/3/26

N2 - OBJECTIVES: Assess the feasibility of a mobile health (mHealth)-supported home-delivered physical activity (PA) intervention (MOTIVATE-T2D) in people with recently diagnosed type 2 diabetes (T2D).DESIGN: Feasibility multicentre, parallel group, randomised controlled trial (RCT).SETTING: Participants were recruited from England and Canada using a decentralised design.PARTICIPANTS: Adults (40-75 years) recently diagnosed with T2D (5-24 months).INTERVENTIONS: Participants were randomised 1:1 to intervention (MOTIVATE-T2D) or active control groups. Participants codesigned 6month- home-delivered, personalised, progressive PA programmes supported by virtual behavioural counselling. MOTIVATE-T2D used biofeedback from wearable technologies to support the programme. The active control group received the same intervention without wearables.OUTCOMES: The primary outcomes were recruitment rate, retention and adherence to purposeful exercise. Clinical data on effectiveness were collected as exploratory outcomes at baseline, 6 and 12 months, with HbA1c and systolic blood pressure (BP) proposed as primary outcomes for a future full RCT.RESULTS: n=135 eligible participants expressed an interest in the trial, resulting in 125 participants randomised (age 55±9 years, 48% female, 81% white), a recruitment rate of 93%. Retention at 12 months was 82%. MOTIVATE-T2D participants were more likely to start (OR 10.4, CI 3.4 to 32.1) and maintain purposeful exercise at 6 (OR 7.1, CI 3.2 to 15.7) and 12 months (OR 2.9, CI 1.2 to 7.4). Exploratory clinical outcomes showed a potential effect in favour of MOTIVATE-T2D, including proposed primary outcomes HbA1c and systolic BP (between-group mean differences: HbA1c: 6 months: -5% change from baseline, CI -10 to 2: 12 months: -2% change from baseline, CI -8 to -4; systolic BP: 6 months: -1 mm Hg, CI -5 to 3: 12 months: -4 mm Hg, CI -8 to 1).CONCLUSIONS: Our findings support the feasibility of delivering the MOTIVATE-T2D mHealth-supported PA intervention for people with recently diagnosed T2D and progression to a full RCT to examine its clinical and cost-effectiveness.TRIAL REGISTRATION NUMBER: ISRCTN: 14335124; ClinicalTrials.gov: NCT0465353.

AB - OBJECTIVES: Assess the feasibility of a mobile health (mHealth)-supported home-delivered physical activity (PA) intervention (MOTIVATE-T2D) in people with recently diagnosed type 2 diabetes (T2D).DESIGN: Feasibility multicentre, parallel group, randomised controlled trial (RCT).SETTING: Participants were recruited from England and Canada using a decentralised design.PARTICIPANTS: Adults (40-75 years) recently diagnosed with T2D (5-24 months).INTERVENTIONS: Participants were randomised 1:1 to intervention (MOTIVATE-T2D) or active control groups. Participants codesigned 6month- home-delivered, personalised, progressive PA programmes supported by virtual behavioural counselling. MOTIVATE-T2D used biofeedback from wearable technologies to support the programme. The active control group received the same intervention without wearables.OUTCOMES: The primary outcomes were recruitment rate, retention and adherence to purposeful exercise. Clinical data on effectiveness were collected as exploratory outcomes at baseline, 6 and 12 months, with HbA1c and systolic blood pressure (BP) proposed as primary outcomes for a future full RCT.RESULTS: n=135 eligible participants expressed an interest in the trial, resulting in 125 participants randomised (age 55±9 years, 48% female, 81% white), a recruitment rate of 93%. Retention at 12 months was 82%. MOTIVATE-T2D participants were more likely to start (OR 10.4, CI 3.4 to 32.1) and maintain purposeful exercise at 6 (OR 7.1, CI 3.2 to 15.7) and 12 months (OR 2.9, CI 1.2 to 7.4). Exploratory clinical outcomes showed a potential effect in favour of MOTIVATE-T2D, including proposed primary outcomes HbA1c and systolic BP (between-group mean differences: HbA1c: 6 months: -5% change from baseline, CI -10 to 2: 12 months: -2% change from baseline, CI -8 to -4; systolic BP: 6 months: -1 mm Hg, CI -5 to 3: 12 months: -4 mm Hg, CI -8 to 1).CONCLUSIONS: Our findings support the feasibility of delivering the MOTIVATE-T2D mHealth-supported PA intervention for people with recently diagnosed T2D and progression to a full RCT to examine its clinical and cost-effectiveness.TRIAL REGISTRATION NUMBER: ISRCTN: 14335124; ClinicalTrials.gov: NCT0465353.

KW - Humans

KW - Diabetes Mellitus, Type 2/therapy

KW - Middle Aged

KW - Female

KW - Male

KW - Feasibility Studies

KW - Exercise

KW - Aged

KW - Telemedicine

KW - Canada

KW - Adult

KW - Patient Compliance

KW - Motivation

KW - United Kingdom

U2 - 10.1136/bmjopen-2024-092260

DO - 10.1136/bmjopen-2024-092260

M3 - Journal article

C2 - 40139900

VL - 15

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 3

M1 - e092260

ER -